Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation

Array to Advance Preclinical Program for Autoimmune Disorders Amgen Responsible for Clinical Development and Worldwide Commercialization THOUSAND OAKS, Calif. and BOULDER, Colo., July 18, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered through Array's proprietary platform that leverages Array's expertise in chemistry and early lead development.  "We are pleased to enter this collaboration with Array that builds on our continued focus in inflammation, one of Amgen's key strategic ar...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news